New drug combo aims to tame deadly transplant complication
NCT ID NCT04339101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack the recipient's body. The study looked at safety and how well the combination worked to keep patients free from GVHD and relapse one year after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itacitinib
What this could lead to
If it works, this could reduce the risk of graft-versus-host disease and improve survival after donor stem cell transplants for blood cancers.
What could go wrong
This is a small, early-phase trial (59 participants) focused on safety and feasibility. The added drug may cause more side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States